A Spiky Silver‐Iron Oxide Nanoparticle for Highly Efficient Targeted Photothermal Therapy and Multimodal Imaging of Thrombosis

Author:

Vazquez‐Prada Karla X.12,Moonshi Shehzahdi S.1,Wu Yuao1,Akther Fahima12,Tse Brian W.C.3,Sokolowski Kamil A.3,Peter Karlheinz45,Wang Xiaowei4,Xu Gordon2,Ta Hang Thu126ORCID

Affiliation:

1. Queensland Micro‐ and Nanotechnology Griffith University Nathan Queensland 4111 Australia

2. Australian Institute for Bioengineering and Nanotechnology the University of Queensland St Lucia Queensland 4072 Australia

3. Translational Research Institute Woolloongabba Queensland 4102 Australia

4. Baker Heart and Diabetes Institute Melbourne Victoria 3004 Australia

5. Department of Medicine Monash University 27 Rainforest Walk Clayton VIC 3800 Australia

6. School of Environment and Science Griffith University Nathan Queensland 4111 Australia

Abstract

AbstractThrombosis and its complications are responsible for 30% of annual deaths. Limitations of methods for diagnosing and treating thrombosis highlight the need for improvements. Agents that provide simultaneous diagnostic and therapeutic activities (theranostics) are paramount for an accurate diagnosis and rapid treatment. In this study, silver‐iron oxide nanoparticles (AgIONPs) are developed for highly efficient targeted photothermal therapy and imaging of thrombosis. Small iron oxide nanoparticles are employed as seeding agents for the generation of a new class of spiky silver nanoparticles with strong absorbance in the near‐infrared range. The AgIONPs are biofunctionalized with binding ligands for targeting thrombi. Photoacoustic and fluorescence imaging demonstrate the highly specific binding of AgIONPs to the thrombus when functionalized with a single chain antibody targeting activated platelets. Photothermal thrombolysis in vivo shows an increase in the temperature of thrombi and a full restoration of blood flow for targeted group but not in the non‐targeted group. Thrombolysis from targeted groups is significantly improved (p < 0.0001) in comparison to the standard thrombolytic used in the clinic. Assays show no apparent side effects of AgIONPs. Altogether, this work suggests that AgIONPs are potential theranostic agents for thrombosis.

Funder

National Health and Medical Research Council

University of Queensland

National Imaging Facility

Publisher

Wiley

Subject

Biomaterials,Biotechnology,General Materials Science,General Chemistry

Reference84 articles.

1. WHO Cardiovascular diseases (CVDs) 2017 https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1.

2. ISTC World Thrombosis Day Empowers People Around the World to Recognize and Help Prevent Life‐Threatening Blood Clots 2019 https://www.prnewswire.com/news-releases/world-thrombosis-day-empowers-people-around-the-world-to-recognize-and-help-prevent-life-threatening-blood-clots-300934190.html.

3. The choice of targets and ligands for site-specific delivery of nanomedicine to atherosclerosis

4. Myocardial Infarction—From Atherosclerosis to Thrombosis

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3